5 reports

  • AMARIN'S DYSLIPIDEMIA PORTFOLIO ASSESSMENT, 2015

PLOS ONE; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

S##. and Rehabilitation; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • MIXED DYSLIPIDEMIA - PIPELINE BY AMGEN INC., H1 2016

Ltd. ## ## ## ## ## Matinas BioPharma Holdings, Inc. ## ## ## ## ## Pfizer Inc. ## ## ## ## ## Thetis Pharmaceuticals LLC ## ## ## ## ## Total ## ## ## ## ## Mixed Dyslipidemia - Pipeline Products Glance COMPARATIVE ANALYSIS BY LATE ST

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.
  • PIPELINE BY AMGEN INC., H1 2016

FH is one of the most common life-threatening genetic diseases, affecting between ## in ## and ## in ## people (##. ##-##. ## per cent).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • HYPERLIPIDEMIA - PIPELINE BY AMGEN INC., H1 2016

It is one of the most common life-threatening genetic diseases, affecting between ## in ## and ## in ## people (##. ## - ##. ## per cent).

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative